HOPE IN RESEARCH
The journey was grueling. Constant travel, side effects, and long stretches away from home tested their endurance. But for 29 remarkable weeks, they witnessed a miracle: Tumors shrank, pain subsided, and Bobby was able to come off all pain medication. Hope returned.
Bobby Senaha’ s Legacy of Hope
When Bobby Senaha was diagnosed with stage-3 pancreatic cancer in late 2022, life as the Senaha family knew it changed in an instant. Just months before, they were in a season of joy— his wife, Dana, had overcome her own health challenges, their two sons were thriving, and Bobby’ s business was flourishing. Then came the diagnosis, and the future they had imagined was suddenly uncertain.
But Bobby chose to face cancer not with fear, but with fierce determination. Even as he underwent 33 weeks of chemotherapy, he refused to let the disease define him. He ran or walked 5K races, lifted weights, and stayed active— fighting to remain strong in every sense of the word. When surgery was no longer an option, Bobby and Dana turned to clinical trials. Their path led them first to Los Angeles, then to San Antonio, Texas, where Bobby became one of the first patients enrolled in a groundbreaking phase 1 trial for RMC-6236— a drug designed to target the aggressive KRAS mutation.
The cancer eventually outpaced the treatment, however, and Bobby passed away peacefully in August 2024. Yet his fight was not in vain. His courageous participation helped propel RMC-6236 into a phase 3 trial— now considered one of the most promising advances in pancreatic cancer care.
And now, that same trial will be available right here in Hawai‘ i, at the UH Cancer Center. No more flights to the continent for this treatment. No more time apart. Patients will have access to this cuttingedge drug while remaining close to their families.
Dana believes Bobby would be deeply proud to know that his journey helped open doors for others. He wasn’ t just fighting for himself— he was fighting for a future where no one has to leave home in search of hope.
Left: Bobby Senaha, Founder of BlackLetter Group, and clinical trial advocate. Above: Bobby, Dana, James, and Jacob Senaha
1 6